Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics

O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors

Philips unveils helium-free 3.0T MRI innovation at RSNA 2025

The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology

FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment

Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor

Imugene reports strong early results for Azer-cel in aggressive blood cancer trial

Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World

The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025

Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval

Now a test that offers new precision in prostate cancer detection

OSR Holdings moves towards major licensing deal for oral cancer immunotherapy

Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate

Medanta launches 550-bed super speciality hospital in Noida

The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs

Investors pile in as Cordance secures oversubscribed seed round for brain-cancer tech

The fresh capital will propel Cordance into its first-in-human clinical trial